Canaccord Genuity analyst Edward Nash maintained a Buy rating on Akero Therapeutics (NASDAQ:AKRO) Inc on Wednesday, setting a price target of $46, which is approximately 41.19% above the present share price of $32.58.
Nash expects Akero Therapeutics Inc to post earnings per share (EPS) of -$0.63 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Akero Therapeutics, with an average price target of $58.
The analysts price targets range from a high of $81 to a low of $46.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$21.54 million. The company's market cap is $1.13 billion.
According to TipRanks.com, Canaccord Genuity analyst Edward Nash is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 7.2% and a 41.99% success rate.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.